Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib plus Everolimus in Advanced RCC
NCT02577458Phase 1Unknown
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorolanib in renal cell carcinoma (RCC), sponsored by AnewPharma Company, Ltd. Primary endpoint: Maximum Tolerated Dose at 12 months. Status: unknown.
02
Drugs
vorolanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02577458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577458.